CY1110793T1 - Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα - Google Patents

Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα

Info

Publication number
CY1110793T1
CY1110793T1 CY20101100846T CY101100846T CY1110793T1 CY 1110793 T1 CY1110793 T1 CY 1110793T1 CY 20101100846 T CY20101100846 T CY 20101100846T CY 101100846 T CY101100846 T CY 101100846T CY 1110793 T1 CY1110793 T1 CY 1110793T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
acid molecules
improved efficiency
tuberculosis vaccine
relates
Prior art date
Application number
CY20101100846T
Other languages
English (en)
Inventor
Leander Grode
Stefan H E Kaufmann
Bärbel Raupach
Jürgen Hess
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of CY1110793T1 publication Critical patent/CY1110793T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με νέα ανασυνδυασμένα εμβόλια τα οποία παρέχουν προστατευτική ανοσία εναντίον της φυματίωσης. Περαιτέρω, η παρούσα εφεύρεση αναφέρεται σε νέα ανασυνδυασμένα μόρια νουκλεϊκού οξέος, φορείς που περιέχουν τα εν λόγω μόρια νουκλεϊκού οξέος, κύτταρα μετασχηματιζόμενα με τα εν λόγω μόρια νουκλεϊκού οξέος και πολυπεπτίδια κωδικοποιούμενα από τα εν λόγω μόρια νουκλεϊκού οξέος.
CY20101100846T 2003-04-23 2010-09-16 Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα CY1110793T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
EP04729090A EP1618128B1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (1)

Publication Number Publication Date
CY1110793T1 true CY1110793T1 (el) 2015-06-10

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100846T CY1110793T1 (el) 2003-04-23 2010-09-16 Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα

Country Status (24)

Country Link
US (2) US7988980B2 (el)
EP (1) EP1618128B1 (el)
JP (1) JP4662925B2 (el)
KR (1) KR101101263B1 (el)
CN (1) CN1798762B (el)
AT (1) ATE473238T1 (el)
AU (1) AU2004232485B2 (el)
BR (1) BRPI0409789B8 (el)
CA (1) CA2523084C (el)
CU (1) CU23608A3 (el)
CY (1) CY1110793T1 (el)
DE (1) DE602004028000D1 (el)
DK (1) DK1618128T3 (el)
ES (1) ES2344698T3 (el)
HK (1) HK1091217A1 (el)
HR (1) HRP20100395T1 (el)
MX (1) MXPA05011360A (el)
PL (1) PL1618128T3 (el)
PT (1) PT1618128E (el)
RU (1) RU2342400C2 (el)
SI (1) SI1618128T1 (el)
UA (1) UA91180C2 (el)
WO (1) WO2004094469A1 (el)
ZA (1) ZA200508276B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE473238T1 (de) * 2003-04-23 2010-07-15 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ZA200704765B (en) 2004-12-01 2008-09-25 Aeras Global Tb Vaccine Found Recombinant BCG strains with enhanced ability to escape the endosome
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
RU2586774C2 (ru) 2010-08-27 2016-06-10 Пантархей Байосайенс Б.В. Иммунотерапевтический способ лечения рака простаты
AU2011304385B2 (en) * 2010-09-20 2015-02-26 Vakzine Projekt Management Gmbh Recombinant Mycobacterium as vaccine for use in humans
WO2012062861A1 (en) 2010-11-10 2012-05-18 Laboratorios Leti, S.L. New adjuvant
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka
BR112013015878B1 (pt) * 2010-12-21 2020-10-27 Vakzine Projekt Management Gmbh método para determinação da eficácia de uma vacina e kit de reagentes
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
RU2760580C2 (ru) * 2017-04-07 2021-11-29 Ченду Йоньгань Фармасьютикал Ко., Лтд. РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR
CN111133412A (zh) * 2017-07-25 2020-05-08 奥罗拉实验室有限公司 基于工具链构建车辆ecu软件的软件增量更新和异常检测
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
IL310225A (en) 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
ATE473238T1 (de) * 2003-04-23 2010-07-15 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz

Also Published As

Publication number Publication date
EP1618128B1 (en) 2010-07-07
CA2523084A1 (en) 2004-11-04
US20070134267A1 (en) 2007-06-14
RU2005136354A (ru) 2006-03-20
UA91180C2 (ru) 2010-07-12
ZA200508276B (en) 2006-06-28
US20120027794A1 (en) 2012-02-02
US8545854B2 (en) 2013-10-01
PL1618128T3 (pl) 2010-12-31
BRPI0409789A (pt) 2006-05-30
JP4662925B2 (ja) 2011-03-30
JP2007524367A (ja) 2007-08-30
KR20050114281A (ko) 2005-12-05
RU2342400C2 (ru) 2008-12-27
CN1798762B (zh) 2010-04-28
US7988980B2 (en) 2011-08-02
PT1618128E (pt) 2010-10-13
ATE473238T1 (de) 2010-07-15
HK1091217A1 (en) 2007-01-12
AU2004232485A1 (en) 2004-11-04
SI1618128T1 (sl) 2010-11-30
KR101101263B1 (ko) 2012-01-04
HRP20100395T1 (hr) 2010-09-30
MXPA05011360A (es) 2005-11-28
CA2523084C (en) 2012-09-04
WO2004094469A1 (en) 2004-11-04
DK1618128T3 (da) 2010-10-18
CU23608A3 (es) 2010-12-08
CN1798762A (zh) 2006-07-05
BRPI0409789B1 (pt) 2018-10-16
EP1618128A1 (en) 2006-01-25
DE602004028000D1 (de) 2010-08-19
ES2344698T3 (es) 2010-09-03
BRPI0409789B8 (pt) 2021-05-25
AU2004232485B2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
CY1106350T1 (el) Εμβολιο φυματιωσης
NO20072470L (no) Malariaigangsetter/forsterkervaksine
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1116149T1 (el) Αντισωματα anti-tnf, συνθεσεις, μεθοδοι και χρησεις αυτων
WO2007062656A3 (en) A nucleotide vaccine
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
CY1114584T1 (el) Ανασυνδυασμενα εμβολια και χρηση αυτων
CY1113970T1 (el) Κατασκευες και φορεις μεταφορας αντιγονων
DK1731605T3 (da) Cancerantigenpeptider der er afledt af WT1
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1105447T1 (el) Μεσο βελτιωσης της ανοσοαποκρισης
CY1110024T1 (el) Πολυπεπτιδια που εχουν αντιμικροβιακη δραστικοτητα και πολυνουκλεοτιδια που τα κωδικοποιουν
ZA202300548B (en) Self-amplifying sars-cov-2 rna vaccine
CY1106433T1 (el) Εμβολια κοκκιδιωσης
CY1111774T1 (el) Csf3r πολυπεπτιδια και χρησεις αυτων
CY1115832T1 (el) Πεπτιδια που προερχονται απο fviii και η χρηση τους στην επαγωγη ανοχης των αιμορροφιλικων
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
DK1740206T3 (da) PHEP, en aminosyrepermease af Staphylococcus Aureus
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
SE0101519D0 (sv) Nucleic ACID